Year archive

Antengene Corporation Limited — 2022 filings

All 62 regulatory filings released by Antengene Corporation Limited (6996) in 2022, sourced directly from the official regulator.

62 Filings

2022 Period

2022 filings (62)

Filing	Released	Lang
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2022-12-16	English
RETIREMENT OF EXECUTIVE DIRECTOR AND APPOINTMENT OF CHIEF MEDICAL OFFICER (CMO) Board/Management Information	2022-12-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022 Regulatory Filings	2022-12-02	English
Next Day Disclosure Return Share Issue/Capital Change	2022-11-25	English
VOLUNTARY ANNOUNCEMENT ENCOURAGING CLINICAL EFFICACY RESULTS OF ATG-008 IN COMBINATION WITH PD-1 ANTIBODY IN RELAPSED/METASTATIC CERVICAL CANCER Regulatory Filings	2022-11-15	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022 Share Issue/Capital Change	2022-11-03	English
VOLUNTARY ANNOUNCEMENT IND APPROVAL FOR THE PHASE I STAMINA-001 STUDY TO EVALUATE ATG-037 (CD73 INHIBITOR) FOR THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC SOLID TUMORS IN CHINA Regulatory Filings	2022-11-02	English
CLARIFICATION AND ACTUAL GRANT OF RSUs AND ISSUE OF NEW SHARES UNDER 2022 GENERAL MANDATE PURSUANT TO THE 2022 RSU SCHEME Share Issue/Capital Change	2022-11-01	English
VOLUNTARY ANNOUNCEMENT U.S. FDA IND CLEARANCE FOR PHASE I TRIAL OF SMALL MOLECULE ERK1/2 INHIBITOR ATG-017 IN PATIENTS WITH ADVANCED SOLID TUMORS Regulatory Filings	2022-10-31	English
VOLUNTARY ANNOUNCEMENT NDA APPROVAL IN TAIWAN FOR ATG-010 (SELINEXOR) FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND DIFFUSE LARGE B-CELL LYMPHOMA Regulatory Filings	2022-10-21	English
Next Day Disclosure Return Share Issue/Capital Change	2022-10-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022 Regulatory Filings	2022-09-30	English
Next Day Disclosure Return Transaction in Own Shares	2022-09-27	English
Notification Letter and Request Form to Non-Registered Shareholders Report Publication Announcement	2022-09-23	English
2022 INTERIM REPORT Interim / Quarterly Report H1 2022	2022-09-23	English
PROPOSED GRANT OF RSUs AND ISSUE OF NEW SHARES UNDER 2022 GENERAL MANDATE PURSUANT TO THE 2022 RSU SCHEME Share Issue/Capital Change	2022-09-22	English
Next Day Disclosure Return Transaction in Own Shares	2022-09-20	English
Next Day Disclosure Return Transaction in Own Shares	2022-09-19	English
Next Day Disclosure Return Transaction in Own Shares	2022-09-16	English
Next Day Disclosure Return Transaction in Own Shares	2022-09-15	English
Next Day Disclosure Return Transaction in Own Shares	2022-09-14	English
Next Day Disclosure Return Share Issue/Capital Change	2022-09-07	English
Next Day Disclosure Return Transaction in Own Shares	2022-09-06	English
VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENT Regulatory Filings	2022-09-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022 Regulatory Filings	2022-09-05	English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2022 Interim / Quarterly Report H1 2022	2022-08-30	English
NOTICE OF DATE OF BOARD MEETING Report Publication Announcement	2022-08-18	English
DISCLOSEABLE TRANSACTION CONSTRUCTION AGREEMENT Capital/Financing Update	2022-08-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022 Share Issue/Capital Change	2022-08-03	English
VOLUNTARY ANNOUNCEMENT REVENUE GROWTH FOR THE PERIOD FROM JANUARY 1, 2022 TO JUNE 30, 2022 Capital/Financing Update	2022-07-28	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022 Regulatory Filings	2022-07-06	English
VOLUNTARY ANNOUNCEMENT ACKNOWLEDGEMENT OF CTN BY THE TGA FOR PHASE I CLINICAL TRIAL OF ATG-018 IN ADVANCED SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES Regulatory Filings	2022-06-23	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022 Regulatory Filings	2022-06-06	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 1, 2022 Declaration of Voting Results & Voting Rights Announcements	2022-06-01	English
CHANGE OF VENUE OF THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 1, 2022 AGM Information	2022-05-17	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022 Regulatory Filings	2022-05-06	English
NOTICE OF THE ANNUAL GENERAL MEETING AGM Information	2022-04-21	English
Notification Letter and Request Form to Non-Registered Shareholders Report Publication Announcement	2022-04-21	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING AGM Information	2022-04-21	English
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING AGM Information	2022-04-21	English
2021 ANNUAL REPORT Regulatory Filings	2022-04-21	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022 Regulatory Filings	2022-04-06	English
CHANGE OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES Board/Management Information	2022-03-30	English
VOLUNTARY ANNOUNCEMENT IND APPROVAL IN CHINA FOR A PHASE II STUDY OF ELTANEXOR (ATG-016) IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES Regulatory Filings	2022-03-30	English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2021 Annual Report FY 2021	2022-03-18	English
VOLUNTARY ANNOUNCEMENT IND APPROVAL IN CHINA FOR THE PHASE I STUDY OF ATG-101 FOR THE TREATMENT OF SOLID TUMORS AND NON-HODGKIN LYMPHOMA Regulatory Filings	2022-03-10	English
VOLUNTARY ANNOUNCEMENT IND APPROVAL IN CHINA FOR THE PHASE I STUDY OF ATG-101 FOR THE TREATMENT OF SOLID TUMORS AND NON-HODGKIN LYMPHOMA Regulatory Filings	2022-03-10	English
TGA IN AUSTRALIA APPROVES XPOVIO (SELINEXOR) FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND TRIPLE CLASS-REFRACTORY MULTIPLE MYELOMA Regulatory Filings	2022-03-09	English
NOTICE OF DATE OF BOARD MEETING Regulatory Filings	2022-03-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022 Regulatory Filings	2022-03-04	English
VOLUNTARY ANNOUNCEMENT APPROVAL OF NDA BY THE SINGAPORE HSA FOR XPOVIO (SELINEXOR) FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND DIFFUSE LARGE B-CELL LYMPHOMA IN THREE INDICATIONS Regulatory Filings	2022-03-01	English
(Revised) Next Day Disclosure Return Transaction in Own Shares	2022-02-22	English
Next Day Disclosure Return Share Issue/Capital Change	2022-02-22	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022 Regulatory Filings	2022-02-09	English
ADOPTION OF THE 2022 RESTRICTED SHARE UNIT SCHEME Capital/Financing Update	2022-01-24	English
Next Day Disclosure Return Share Issue/Capital Change	2022-01-17	English
Next Day Disclosure Return Transaction in Own Shares	2022-01-13	English
Next Day Disclosure Return Transaction in Own Shares	2022-01-07	English
Next Day Disclosure Return Transaction in Own Shares	2022-01-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021 Transaction in Own Shares	2022-01-06	English
Next Day Disclosure Return Transaction in Own Shares	2022-01-05	English
Next Day Disclosure Return Transaction in Own Shares	2022-01-04	English